Prime Medicine Peer Comparison

$5.14

$0.79 (18.05%)

As on 28-Oct-2026 12:33EDT

Market cap

$666 Mln

Revenue (TTM)

$4 Mln

P/E Ratio

--

P/B Ratio

19.5

Div. Yield

0 %

Edit

	Prime Medicine	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Pharming Group N.V. ADS each representing 10 (PHAR)
Market cap ($ Mln)	666	2,698	2,496	1,595	793
Revenue ($ Mln)	4	450	549	121	366
Net Profit ($ Mln)	-187.89	-188.21	17.88	-57.76	9.27
Net Margin (%)	-4,613.11	-41.86	3.26	-47.60	2.53
RoE (%)	-233.88	-28.46	1.43	-9.91	3.39
Price to Earnings	--	--	143.60	--	86.15
Price-To-Book	19.54	4.56	2.25	3.65	2.95

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Prime Medicine	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Pharming Group N.V. ADS each representing 10 (PHAR)
Operating Revenue	4.07	449.61	549.12	120.79	366.45
Cost of Revenue	47.72	195.71	548.01	19.21	49.36
Gross Profit	-2.69	269.08	212.72	12.07	330.63
Operating Expenses	154.75	517.90	35.89	154.86	304.74
Operating Profit (EBIT)	-196.52	-264.00	-34.78	-118.11	12.35
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-187.89	-190.72	20.08	-57.14	15.84
Provision for Tax	0.00	-2.51	1.66	0.62	6.57
Profit after Tax (Net Income)	-187.89	-188.21	17.88	-57.50	9.27
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	0.00	0.00	0.00	0.00

Liabilities ($ Mln)

	Prime Medicine	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Pharming Group N.V. ADS each representing 10 (PHAR)
Shareholder's Funds	39.81	607.04	1,260.78	568.41	270.49
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	177.54	39.17	186.25	123.56	104.25
Current Liabilities	31.69	428.58	275.21	81.11	93.25
Total Liabilities	342.73	1,172.38	1,753.10	784.68	499.81

Assets ($ Mln)

	Prime Medicine	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Pharming Group N.V. ADS each representing 10 (PHAR)
Non-Current Assets	152.24	160.76	183.02	575.59	187.30
Current Assets	96.80	914.04	1,553.41	197.49	280.69
Total Assets	342.73	1,172.38	1,753.10	784.68	499.81
Total Debt*	112.48	254.58	94.51	127.33	113.30
Net Current Assets	65.11	485.45	0.00	116.38	187.44

Cashflow ($ Mln)

	Prime Medicine	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Pharming Group N.V. ADS each representing 10 (PHAR)
Cash From Operating Activities	-162.56	-150.79	-64.66	-49.95	54.71
Cash Flow from Investing Activities	-108.76	307.87	-29.41	0.12	26.25
Cash from Financing Activities	151.51	72.35	7.84	147.34	1.50
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Prime Medicine	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Pharming Group N.V. ADS each representing 10 (PHAR)
ROCE (%)	-93.29	-18.15	41.92	-15.42	0.77
ROE (%)	-233.88	-28.46	1.43	-10.06	3.39
ROA (%)	-63.28	-12.55	0.66	-6.60	1.69
EBIT Margin (%)	-4,613.11	-41.09	-6.33	-42.43	8.34
Net Margin (%)	-4,613.11	-41.86	3.26	-47.60	2.53
Cash Profit Margin (%)	0.00	0.00	--	--	0.00

Growth Ratios

	Prime Medicine	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Pharming Group N.V. ADS each representing 10 (PHAR)
Revenue Growth (%)	-17.90	5.10	-8.81	602.33	-99.61
EBIT Growth (%)	5.71	11.36	-76.55	17.93	523.06
Net Profit Growth (%)	5.71	11.44	-96.17	43.71	-99.68
EPS Growth (%)	28.69	-1.87	-96.17	47.43	-96.78
Book Value Growth (%)	-52.32	-25.05	2.54	-6.65	7.71

Valuation Ratios

	Prime Medicine	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Pharming Group N.V. ADS each representing 10 (PHAR)
Price / Earnings	-2.57	-11.11	5.08	-13.58	469.58
Price / Book Value	4.27	2.73	1.88	2.32	4.83
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	-2.32	-9.39	-25.56	-18.38	36.65
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Prime Medicine	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Pharming Group N.V. ADS each representing 10 (PHAR)
Debt to Equity	0.00	0.00	0.00	0.19	0.34
Short term debt to equity ratio	0.23	0.40	0.02	0.02	0.03
Current Ratio	3.05	2.13	5.64	2.43	3.01
Quick Ratio	3.05	1.92	5.50	2.09	2.31
Interest Coverage	--	-30.87	-19.05	-4.06	2.08

Operating Efficiency Ratios

	Prime Medicine	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Pharming Group N.V. ADS each representing 10 (PHAR)
Debtors to sales (%)	0.00	16.23	21.41	47.25	15.55
Asset Turnover	0.01	0.30	0.20	0.14	0.67
Receivable days	--	77.60	104.79	380.35	51.78
Inventory Days	--	109.55	49.57	791.94	492.02
Payable days	504.84	231.78	47.68	931.00	466.91
Cash Conversion Cycle	--	-44.63	106.67	241.30	76.89

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly